| pubmed-article:11951055 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11951055 | lifeskim:mentions | umls-concept:C0684336 | lld:lifeskim |
| pubmed-article:11951055 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:11951055 | lifeskim:mentions | umls-concept:C0009649 | lld:lifeskim |
| pubmed-article:11951055 | lifeskim:mentions | umls-concept:C0165264 | lld:lifeskim |
| pubmed-article:11951055 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11951055 | pubmed:dateCreated | 2002-4-12 | lld:pubmed |
| pubmed-article:11951055 | pubmed:abstractText | The cognition-enhancing drug, nefiracetam, is in Phase III clinical trials to treat memory impairment in Alzheimer's disease (AD). Nefiracetam ameliorates acquisition of delay eyeblink classical conditioning in older rabbits, a form of associative learning with striking behavioral and neurobiological similarities in rabbits and humans. In both species, delay eyeblink conditioning engages the septo-hippocampal cholinergic system and is disrupted when the cholinergic system is antagonized. Delay eyeblink classical conditioning is impaired in normal aging and severely disrupted in AD. | lld:pubmed |
| pubmed-article:11951055 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11951055 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11951055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11951055 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11951055 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11951055 | pubmed:issn | 1234-1010 | lld:pubmed |
| pubmed-article:11951055 | pubmed:author | pubmed-author:GreenJohnJ | lld:pubmed |
| pubmed-article:11951055 | pubmed:author | pubmed-author:PakJonathanJ | lld:pubmed |
| pubmed-article:11951055 | pubmed:author | pubmed-author:HeifetsBorisB | lld:pubmed |
| pubmed-article:11951055 | pubmed:author | pubmed-author:PakMichelleM | lld:pubmed |
| pubmed-article:11951055 | pubmed:author | pubmed-author:Woodruff-PakD... | lld:pubmed |
| pubmed-article:11951055 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11951055 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:11951055 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11951055 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11951055 | pubmed:pagination | BR105-12 | lld:pubmed |
| pubmed-article:11951055 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:meshHeading | pubmed-meshheading:11951055... | lld:pubmed |
| pubmed-article:11951055 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:11951055 | pubmed:articleTitle | Nefiracetam ameliorates associative learning impairment in the scopolamine-injected older rabbit. | lld:pubmed |
| pubmed-article:11951055 | pubmed:affiliation | Cognitive Neuroscience Laboratory, Albert Einstein Healthcare Network, Philadelphia, PA 19141, USA. | lld:pubmed |
| pubmed-article:11951055 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11951055 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
